Human Genome Sciences Reports Positive Interim Quality-of-Life Data

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=1115342 & channelID=31

Human Genome Sciences Reports Positive Interim Quality-of-Life Data From

Ph..

PR Newswire Europe (inc. UK Disclose) - 16-Oct-2006

The interim results demonstrate that all Albuferon treatment groups

consistently performed favorably through Week 12 compared to the pegylated

interferon alpha treatment group, based on patient-reported disability days

and health-related quality of life as measured by the SF-36 health survey.

This technology enables scientists to improve the pharmacological properties

of therapeutic proteins by fusing the gene that expresses human albumin to

the gene that expresses the active protein

Summary

• ROCKVILLE, Md., Oct. 16 /PRNewswire-FirstCall/ -- Human Genome Sciences,

Inc. today reported 12-week interim quality-of-life results from a Phase 2b

clinical trial to evaluate the efficacy, safety and impact on health-related

quality of life of Albuferon in combination with ribavirin in patients

with genotype 1 chronic hepatitis C (HCV) who are naive to interferon

alpha-based treatment regimens.

• The interim results demonstrate that all Albuferon treatment groups

consistently performed favorably through Week 12 compared to the pegylated

interferon alpha treatment group, based on patient-reported disability days

and health-related quality of life as measured by the SF-36 health survey.

• The data were presented over this past weekend at the annual Australian

Gastroenterology Week in Adelaide.

• " Interim results of the current study suggest that Albuferon may have the

potential to offer a therapeutic alternative with less impairment of

health-related quality of life, and fewer disability days, compared with the

current standard of care, with at least comparable safety and efficacy.

• We look forward to continuing the evaluation of Albuferon to determine its

appropriate role in the treatment of hepatitis C. "

• " Through Week 12 of the Phase 2b study, patients in the Albuferon

treatment groups recorded fewer missed work days and, based on the SF-36

health assessment, reported better quality of life than patients in the

pegylated interferon treatment group, " said C. Stump, M.D., Executive

Vice President, Drug Development, HGS.

• " This result was observed in both the physical and mental component

summary measures, as well as in the 8 individual domain scores.

• The SF-36 results in mental health suggest significantly less impairment

of psychological well-being across the Albuferon treatment groups. "

_________________________________________________________________

Stay in touch with old friends and meet new ones with Windows Live Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://spaces.\

live.com/spacesapi.aspx?wx_action=create & wx_url=/friends.aspx & mkt=en-us

[Guest guest]

http://www.therapeuticsdaily.com/news/summary.cfm?id=1115342 & channelID=31

Human Genome Sciences Reports Positive Interim Quality-of-Life Data From

Ph..

PR Newswire Europe (inc. UK Disclose) - 16-Oct-2006

The interim results demonstrate that all Albuferon treatment groups

consistently performed favorably through Week 12 compared to the pegylated

interferon alpha treatment group, based on patient-reported disability days

and health-related quality of life as measured by the SF-36 health survey.

This technology enables scientists to improve the pharmacological properties

of therapeutic proteins by fusing the gene that expresses human albumin to

the gene that expresses the active protein

Summary

• ROCKVILLE, Md., Oct. 16 /PRNewswire-FirstCall/ -- Human Genome Sciences,

Inc. today reported 12-week interim quality-of-life results from a Phase 2b

clinical trial to evaluate the efficacy, safety and impact on health-related

quality of life of Albuferon in combination with ribavirin in patients

with genotype 1 chronic hepatitis C (HCV) who are naive to interferon

alpha-based treatment regimens.

• The interim results demonstrate that all Albuferon treatment groups

consistently performed favorably through Week 12 compared to the pegylated

interferon alpha treatment group, based on patient-reported disability days

and health-related quality of life as measured by the SF-36 health survey.

• The data were presented over this past weekend at the annual Australian

Gastroenterology Week in Adelaide.

• " Interim results of the current study suggest that Albuferon may have the

potential to offer a therapeutic alternative with less impairment of

health-related quality of life, and fewer disability days, compared with the

current standard of care, with at least comparable safety and efficacy.

• We look forward to continuing the evaluation of Albuferon to determine its

appropriate role in the treatment of hepatitis C. "

• " Through Week 12 of the Phase 2b study, patients in the Albuferon

treatment groups recorded fewer missed work days and, based on the SF-36

health assessment, reported better quality of life than patients in the

pegylated interferon treatment group, " said C. Stump, M.D., Executive

Vice President, Drug Development, HGS.

• " This result was observed in both the physical and mental component

summary measures, as well as in the 8 individual domain scores.

• The SF-36 results in mental health suggest significantly less impairment

of psychological well-being across the Albuferon treatment groups. "

_________________________________________________________________

Stay in touch with old friends and meet new ones with Windows Live Spaces

http://clk.atdmt.com/MSN/go/msnnkwsp0070000001msn/direct/01/?href=http://spaces.\

live.com/spacesapi.aspx?wx_action=create & wx_url=/friends.aspx & mkt=en-us